Appili Therapeutics Inc. (APLI.TO)
- Business Wire
Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program
HALIFAX, Nova Scotia, January 17, 2023--Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, has named Carl Gelhaus, Ph.D., as Director of Non-Clinical Research, and Arthur Baran, B.Sc., MBA, PMP, as Director of New Product Development including ATI-1701, a potential first-in-class vaccine candidate for the prevention of infection with aerosolized Francisella tularensis, whi
- Baystreet
Stocks in play: Appili Therapeutics Inc.
Announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance ...
- Business Wire
Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole
HALIFAX, Nova Scotia, January 13, 2023--Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance of new patent claims for ATI-1501, Appili’s liquid oral reformulation of the antibiotic metronidazole. A notice of allowance is issued by the USPTO to indicate that t
